|
|
| | KPT-8602 Basic information |
| Product Name: | KPT-8602 | | Synonyms: | KPT-8602;Eltanexor
(KPT-8602;CS-2388;KPT-8602 (KPT 8602;Eltanexor;5-Pyrimidineacetamide, α-[[3-[3,5-bis(trifluoromethyl)phenyl]-1H-1,2,4-triazol-1-yl]methylene]-, (αE)-;(E)-3-(3-(3,5-Bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-(pyrimidin-5-yl)acrylamide;ATG-016 | | CAS: | 1642300-52-4 | | MF: | C17H10F6N6O | | MW: | 428.3 | | EINECS: | | | Product Categories: | | | Mol File: | 1642300-52-4.mol |  |
| | KPT-8602 Chemical Properties |
| Boiling point | 574.4±60.0 °C(Predicted) | | density | 1.57±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 13.06±0.50(Predicted) |
| | KPT-8602 Usage And Synthesis |
| Uses | (αE)?-α-?[[3-?[3,?5-?bis(Trifluoromethyl)?phenyl]?-?1H-?1,?2,?4-?triazol-?1-?yl]?methylene]?-?5-pyrimidineacetamide is an exportin-1 inhibitor with anti-leukemic activity. Exportin-1 mediates nuclear trafficking of proteins. (αE)?-α-?[[3-?[3,?5-?bis(Trifluoromethyl)?phenyl]?-?1H-?1,?2,?4-?triazol-?1-?yl]?methylene]?-?5-pyrimidineacetamide can be used to develop treatments for acute lymphoblastic leukemia. |
| | KPT-8602 Preparation Products And Raw materials |
|